Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Wu TH
------>authors3_c=
------>paper_class1=1
------>Impact_Factor=2.802
------>paper_class3=2
------>paper_class2=1
------>vol=x
------>confirm_bywho=amel
------>insert_bywho=thwu
------>Jurnal_Rank=27.4
------>authors4_c=
------>comm_author=
------>patent_EDate=None
------>authors5_c=
------>publish_day=5
------>paper_class2Letter=None
------>page2=press
------>medlineContent=
------>unit=G0100
------>insert_date=20081027
------>iam=1
------>update_date=None
------>author=???
------>change_event=4
------>ISSN=
------>authors_c=
------>score=500
------>journal_name=Prog Neuropsychopharmacol Biol Psychiatry.
------>paper_name=Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors.
------>confirm_date=20081127
------>tch_id=091080
------>pmid=18796323
------>page1=in
------>fullAbstract=Tobacco consumption has been recognized as a factor mediating the interindividual variations in olanzapine~s pharmacokinetics and pharmacodynamics. The primary objective of this study was to describe the dose effect of smoking on the dose-plasma concentration relationship and the pharmacokinetics of oral olanzapine in male schizophrenic patients using high-performance liquid chromatography coupled with electrochemical detector. Twenty-seven male schizophrenic inpatients were recruited and were stratified into the following groups according to smoking behaviors: non-smokers (n=9), light-smokers (1-4 cigarettes per day; n=9), and heavy-smokers (>or=5 cigarettes per day; n=9). Plasma olanzapine concentrations were determined up to 120 h following a single oral dose of 10 mg olanzapine. The pharmacokinetic parameters were calculated by the non-compartment method using WinNonlin software. Results show that there was a significant correlation among non-smokers (n=9; 0.79; p=0.01) or combined with light-smokers (n=18; 0.62; p<0.01) between peak plasma olanzapine concentrations (Cmax) and their individual dose-corrected by body weight, but this correlation did not appear in heavy-smokers. There were no significant differences between non-smokers and light-smokers except for significant decreased AUC0-->120 by 45.1% in light-smokers. The mean C(max) and the mean area under the plasma concentration-time curve from time zero to 120 h (AUC0-->120) of the heavy-smoking patients was 9.3+/-4.3 ng/ml (65.2% reduction compared to the non-smokers) and 302.4+/-167.8 h ng/ml (67.6% reduction compared to the non-smokers), respectively. In summary, a daily consumption of 5 cigarettes is probably sufficient for induction of olanzapine metabolism. Smoking cessation is recommended for olanzapine therapy to have better prediction for therapeutic dosages particularly in heavy-smokers. Compared to non-smokers, heavy-smokers therefore require a 50-100% increase in olanzapine doses. Therapeutic drug monitoring will need to be considered when schizophrenic patients change their smoking behaviors.
------>tmu_sno=None
------>sno=18929
------>authors2=Chiu CC
------>authors3=Shen WW
------>authors4=Lin FW
------>authors5=Wang LH
------>authors6=Chen HY, Lu ML
------>authors6_c=
------>authors=Wu TH
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=
------>publish_area=0
------>updateTitle=Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors.
------>language=2
------>check_flag=None
------>submit_date=None
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=None
------>publish_year=2008
------>submit_flag=None
------>publish_month=9
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z